A detailed history of Black Rock Inc. transactions in Erasca, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 10,611,346 shares of ERAS stock, worth $34.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,611,346
Previous 6,981,170 52.0%
Holding current value
$34.3 Million
Previous $14.4 Million 74.13%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.79 - $2.63 $6.5 Million - $9.55 Million
3,630,176 Added 52.0%
10,611,346 $25 Million
Q1 2024

May 10, 2024

SELL
$1.67 - $2.55 $549,682 - $839,335
-329,151 Reduced 4.5%
6,981,170 $14.4 Million
Q4 2023

Feb 13, 2024

BUY
$1.67 - $2.49 $472,740 - $704,864
283,078 Added 4.03%
7,310,321 $15.6 Million
Q3 2023

Nov 13, 2023

BUY
$1.97 - $2.91 $216,875 - $320,358
110,089 Added 1.59%
7,027,243 $13.8 Million
Q2 2023

Aug 11, 2023

BUY
$2.57 - $3.3 $3.97 Million - $5.1 Million
1,545,305 Added 28.77%
6,917,154 $19.1 Million
Q1 2023

May 12, 2023

BUY
$2.74 - $4.44 $1.04 Million - $1.68 Million
378,302 Added 7.58%
5,371,849 $16.2 Million
Q4 2022

Feb 13, 2023

BUY
$3.89 - $8.57 $800,383 - $1.76 Million
205,754 Added 4.3%
4,993,547 $21.5 Million
Q3 2022

Nov 14, 2022

BUY
$5.82 - $10.68 $3.12 Million - $5.72 Million
535,420 Added 12.59%
4,787,793 $37.3 Million
Q2 2022

Aug 12, 2022

BUY
$4.58 - $8.72 $1.84 Million - $3.51 Million
401,963 Added 10.44%
4,252,373 $23.7 Million
Q1 2022

May 12, 2022

BUY
$8.6 - $15.48 $16.9 Million - $30.4 Million
1,961,965 Added 103.89%
3,850,410 $33.1 Million
Q4 2021

Feb 10, 2022

BUY
$12.51 - $22.75 $8.5 Million - $15.5 Million
679,629 Added 56.22%
1,888,445 $29.4 Million
Q3 2021

Nov 09, 2021

BUY
$17.43 - $24.34 $21.1 Million - $29.4 Million
1,208,816 New
1,208,816 $25.7 Million

Others Institutions Holding ERAS

About Erasca, Inc.


  • Ticker ERAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,147,000
  • Market Cap $395M
  • Description
  • Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...
More about ERAS
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.